Ligand News and Research

RSS

Study finds several flavor/fragrance compositions that inhibit vRBD-hACE2 binding

A study describes the antiviral activity of flavor/fragrance compositions against SARS-CoV-2.

20 Dec 2022

Extraordinary plasticity of the glucocorticoid receptor revealed

Glucocorticoids —such as cortisone— are among the most widely used anti-inflammatory drugs, and are used to treat asthma, psoriasis, organ transplantation and even COVID-19.

15 Dec 2022

The therapeutic effects and safety of psychedelics

Psychedelics are reported to have rapid-onset and long-lasting therapeutic benefits after a single or few doses.

14 Dec 2022

The implications of pulmonary tissue-resident memory T lymphocytes in COVID-19 and other respiratory diseases

Researchers elucidated the mechanisms of long-term T lymphocyte lodgement in tissues other than lymphoid tissues and the reasons for the transient residency of specific subsets of tissue-resident memory T (TRM) lymphocytes.

14 Dec 2022

Research reveals the assembly dynamics of nucleocapsid protein condensates can be regulated by small molecules with therapeutic potential

Researchers developed a screening platform and identified molecules with anti-CoV activity.

12 Dec 2022

Shenandoah Biotechnology introduces expanded range of CTGrade recombinant proteins manufactured following cGMP practices

Shenandoah Biotechnology Inc., a FUJIFILM Irvine Scientific company and leading manufacturer of recombinant proteins, today announced it has expanded its CTGrade portfolio of cytokines and growth factors for cell and gene therapies manufactured following cGMP guidelines.

From FUJIFILM Irvine Scientific 7 Dec 2022

Comparison of blood plasma protein expression in mild, moderate, and severe COVID-19 identifies novel disease severity biomarkers

Researchers evaluated blood plasma proteins to identify new targets for COVID-19 treatment approaches and prevent complications associated with severe illness.

5 Dec 2022

Researchers develop a polyvalent lipid nanoparticle mRNA vaccine against Monkeypox virus

Researchers developed an mRNA technology-based vaccine candidate against the monkeypox virus and evaluated its immunogenicity in animal models.

5 Dec 2022

Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the launch of its High Throughput Screening (HTS) capability, as well as the expansion of its state-of-the-art lab and office facilities. Scott Maidment has been appointed as Head of HTS to lead the new service.

From Metrion Biosciences Limited 1 Dec 2022

Study reveals key details of how DREADD technology highjacks neuronal activity

Understanding of how neuronal activity modulates brain function is a key first step towards creating more effective drugs to treat a variety of neuropsychiatric illnesses, including depression, anxiety, schizophrenia, substance abuse, epilepsy, and others.

30 Nov 2022

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Researchers used ribonucleic acid (RNA) sequence data to understand the association between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML).

29 Nov 2022

Cryo-electron tomography helps visualize platelet deformation due to SARS-CoV-2 spike protein

Researchers used cellular cryo-electron tomography (cryo-ET) to demonstrate the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in coronavirus disease 2019 (COVID-19)-triggered severe coagulopathies.

28 Nov 2022

Pocket feature in SARS-CoV-2 spike protein is present in all deadly coronaviruses, study reveals

Scientists have discovered why some coronaviruses are more likely to cause severe disease, which has remained a mystery, until now.

24 Nov 2022

New York sewer rats are easily infected by SARS-CoV-2, according to new study

Researchers evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure among rats inhabiting New York City (NYC) during the fall of 2021.

23 Nov 2022

Molecular motion of many 'undruggable' proteins reveals previously unseen binding sites

Studying the molecular motion of proteins reveals previously unseen binding sites that could be targeted by new drug candidate molecules.

21 Nov 2022

SARS-CoV-2 RNA levels, IFN-1, ISGs, and NF-κB gene responses within the respiratory tract of mild and severe COVID-19 patients

Researchers characterized the expression of IFN-1 and IFN-2, ISGs, and NF-κB in the upper respiratory tracts of patients with mild and severe COVID-19, to understand innate immune responses to SARS-CoV-2 infections.

17 Nov 2022

Study identifies novel inhibitors against SARS-CoV-2 main protease

In a recent study posted to the bioRxiv* server, researchers at the University of Arizona screened ~11 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro)-inhibiting small compounds in the ZINC15 database using a structure-based in-silico screening method.

8 Nov 2022

Study refutes the nicotinic hypothesis of SARS-CoV-2 infection mechanism

A new study confirmed that the SARS-CoV-2 spike protein does not bind to human AChR’s orthosteric sites, nor does it compete with ACh, choline, or nicotine.

28 Oct 2022

Association of COVID-19 severity with nasopharyngeal fungal colonization and interleukin-17 induction

Researchers evaluated the concurrent colonization of fungi in the nasopharynx of severe COVID-19 patients.